Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Yonsei Med J. 2010 Jan;51(1):58-68. doi: 10.3349/ymj.2010.51.1.58. Epub 2009 Dec 29.
There is still debate about the timing of revascularization in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI). We analyzed the long-term clinical outcomes of the timing of revascularization in patients with acute NSTEMI obtained from the Korea Acute Myocardial Infarction Registry (KAMIR).
2,845 patients with acute NSTEMI (65.6 +/- 12.5 years, 1,836 males) who were enrolled in KAMIR were included in the present study. The therapeutic strategy of NSTEMI was categorized into early invasive (within 48 hours, 65.8 +/- 12.6 years, 856 males) and late invasive treatment (65.3 +/- 12.1 years, 979 males). The initial- and long-term clinical outcomes were compared between two groups according to the level of Thrombolysis In Myocardial Infarction (TIMI) risk score.
There were significant differences in-hospital mortality and the incidence of major adverse cardiac events during one-year clinical follow-up between two groups (2.1% vs. 4.8%, p < 0.001, 10.0% vs. 13.5%, p = 0.004, respectively). According to the TIMI risk score, there was no significant difference of long-term clinical outcomes in patients with low to moderate TIMI risk score, but significant difference in patients with high TIMI risk score (>or= 5 points).
The old age, high Killip class, low ejection fraction, high TIMI risk score, and late invasive treatment strategy are the independent predictors for the long-term clinical outcomes in patients with NSTEMI.
急性非 ST 段抬高型心肌梗死(NSTEMI)患者血运重建时机仍存在争议。本研究分析了韩国急性心肌梗死注册研究(KAMIR)中急性 NSTEMI 患者血运重建时机的长期临床结局。
本研究纳入了 2845 例急性 NSTEMI 患者(年龄 65.6±12.5 岁,男性 1836 例)。根据 KAMIR,NSTEMI 的治疗策略分为早期侵入性(48 小时内,年龄 65.8±12.6 岁,男性 856 例)和晚期侵入性治疗(年龄 65.3±12.1 岁,男性 979 例)。根据 TIMI 危险评分,比较两组患者的初始和长期临床结局。
两组患者住院期间死亡率和 1 年临床随访期间主要不良心脏事件发生率存在显著差异(2.1% vs. 4.8%,p<0.001;10.0% vs. 13.5%,p=0.004)。根据 TIMI 危险评分,低危和中危 TIMI 评分患者的长期临床结局无显著差异,但高危 TIMI 评分(≥5 分)患者的长期临床结局存在显著差异。
年龄较大、较高的 Killip 分级、较低的射血分数、较高的 TIMI 危险评分和晚期侵入性治疗策略是 NSTEMI 患者长期临床结局的独立预测因素。